Trial Profile
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Cisplatin
- Indications Advanced breast cancer; Brain metastases; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 01 Nov 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 01 Nov 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 06 Jan 2023 Results published in the Lancet Oncology